Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shandong Xinnovi Pharmaceutical Technology, a subsidiary of CSPC Innovation Pharmaceutical (CSPC Xinnovi), is a core manufacturing and research arm within the CSPC Pharmaceutical Group. Based in Zibo, Shandong, the company is a global leader in the production of caffeine and functional food additives, while also serving as a major supplier of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). In recent years, Xinnovi has transitioned into a primary vehicle for the CSPC Group's innovative drug development, integrating advanced clinical assets in metabolic diseases and oncology. Its portfolio now includes high-potential programs such as GLP-1 receptor agonists and monoclonal antibodies. The company operates large-scale, GMP-certified facilities and maintains a significant presence in both domestic and international markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shandong Xinnovi Pharmaceutical Technology.